Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2021 08:00 ET | Source: Endonovo Therapeutics, Inc.

Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward

Los Angeles, CA, May 11, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse® tPEMF Devices for use in...
October 08, 2020 08:00 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.

LOS ANGELES, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today a new marketing and public awareness campaign around their FDA...
September 09, 2020 08:00 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®

LOS ANGELES, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an additional opportunity to view a live webinar presentation...
August 20, 2020 14:51 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results

LOS ANGELES, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced financial and operating results for the second quarter ended...
July 27, 2020 09:00 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®

LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that an investigator initiated study, authored by Dr. Samir...
July 21, 2020 09:00 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing

Los Angeles, CA, July 21, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced the Company’s registration statement on Form S-1 relating...
June 15, 2020 08:00 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results

Los Angeles, CA, June 15, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the first quarter...
June 01, 2020 10:00 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China

Los Angeles, CA, June 01, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the signing of a Sales and Strategic Partnership Agreement...
May 26, 2020 08:18 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund

Agreement Provides Flexible Access to Funding at a Lower Cost of Capital Los Angeles, CA, May 26, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company")...
May 04, 2020 08:15 ET | Source: Endonovo Therapeutics, Inc.

Endonovo Therapeutics Announces Positive 2019 Fiscal Results

Los Angeles, CA, May 04, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today reported financial results for fiscal year ended December 31, 2019. ...

Next Page keyboard_arrow_right